Clinical manifestations, genetic characteristics and laboratory markers of patients with epidermolysis bullosa: a single tertiary referral center experience.

Tubanur Çetinarslan, Abdullah Kutay Masat, Şule Altıner, Işıl İnanır

Abstract read

In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tubanur ÇetinarslanDepartment of Dermatology and Venereology, Manisa Celal Bayar University, Manisa, Turkey.ORCID 0000-0002-2847-9127

Abdullah Kutay MasatDepartment of Dermatology and Venereology, Manisa Celal Bayar University, Manisa, Turkey.

Şule AltınerDepartment of Genetics, Ankara University, Ankara, Turkey.

Işıl İnanırDepartment of Dermatology and Venereology, Manisa Celal Bayar University, Manisa, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpidermolysis bullosa (EB) is a group of genetically and clinically heterogeneous diseases that presents as blisters, erosions, crusts, and scars. MATERIALS AND

methodIn this retrospective study, we report the clinical manifestations, genetic characteristics, and laboratory markers of patients with EB.

resultsFifteen patients with EB were included in the study. The most common type was dystrophic EB (DEB) (

conclusionEB is a genetic disease that may associated with many systemic comorbidities. Multidisciplinary management of wound care is essential for the early management of severe EB to avoid wound progression into scars and deformities. The levels of vitamins such as ferritin and zinc, and the levels of hemoglobin and albumin, should be optimal levels to optimize wound healing.

Indexed as

Epidermolysis BullosaAdolescentAdultBiomarkersBlisterChildChild, PreschoolCollagen Type VIIEpidermolysis Bullosa DystrophicaEpidermolysis Bullosa, JunctionalEpidermolysis Bullosa SimplexFemaleHumansInfantIntegrin beta4Keratin-5BiomarkersCOL7A1 protein, humanCollagen Type VIIFERMT1 protein, humanIntegrin beta4Keratin-5Membrane ProteinsNeoplasm ProteinsPlectinEpidermolysis bullosageneticsnutritionvitamin

Identifiers

PMID42867271

DOI10.1080/07853890.2026.2741779

PMCPMC13665705

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.